Literature DB >> 8530501

Fibroblast growth factor receptors (FGFRs) localize in different cellular compartments. A splice variant of FGFR-3 localizes to the nucleus.

C L Johnston1, H C Cox, J J Gomm, R C Coombes.   

Abstract

We have raised specific antibodies to the second immunoglobulin-like domain of fibroblast growth factor receptors (FGFRs) and used these to investigate the expression and subcellular localization of FGFR-1, -2, -3, and -4 in breast epithelial cells. All four receptors classes could be detected in breast cell lines; however, FGFR-4 and FGFR-2 appeared to be expressed at a higher level in breast cancer cell lines than in normal epithelial cells. Surprisingly, FGFR-3 localized in the cell nucleus by immunofluorescence. A second antibody to a separate epitope confirmed this finding and showed that the form of FGFR-3 present must contain an intact kinase domain as well as the growth factor binding domain. Western analysis of fractionated cells revealed the presence of two forms of FGFR-3 of 135 and 110 kDa. The 110-kDa form was predominantly found in the nucleus, whereas the 135 kDa form was sometimes found in the nucleus. RT-PCR analysis of FGFR-3 mRNA showed the presence of a splice variant in which exons 7 and 8 are deleted. This results in the translation of FGFR-3 missing the transmembrane domain but with an intact kinase domain, which could be a soluble, intracellular receptor. Transfection experiments showed that FGFR-3 containing this deletion and no signal peptide gave an identical nuclear staining pattern to that seen in breast epithelial cells. We conclude that two forms of FGFR-3 are present in breast epithelial cells; a full-length 135-kDa receptor, which has a conventional membrane localization, and a novel soluble form of 110 kDa.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8530501     DOI: 10.1074/jbc.270.51.30643

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor.

Authors:  Dipak K Giri; Mohamed Ali-Seyed; Long-Yuan Li; Dung-Fang Lee; Pin Ling; Geoffrey Bartholomeusz; Shao-Chun Wang; Mien-Chie Hung
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

2.  Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain.

Authors:  M K Webster; D J Donoghue
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

3.  Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.

Authors:  M Chesi; E Nardini; L A Brents; E Schröck; T Ried; W M Kuehl; P L Bergsagel
Journal:  Nat Genet       Date:  1997-07       Impact factor: 38.330

4.  HMGN2 inducibly binds a novel transactivation domain in nuclear PRLr to coordinate Stat5a-mediated transcription.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Yi Liu; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Mol Endocrinol       Date:  2011-08-04

5.  Nuclear accumulation of fibroblast growth factor receptors is regulated by multiple signals in adrenal medullary cells.

Authors:  M K Stachowiak; P A Maher; A Joy; E Mordechai; E K Stachowiak
Journal:  Mol Biol Cell       Date:  1996-08       Impact factor: 4.138

6.  Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer.

Authors:  Juan P Cerliani; Silvia I Vanzulli; Cecilia Pérez Piñero; María C Bottino; Ana Sahores; Myriam Nuñez; Romina Varchetta; Rubén Martins; Eduardo Zeitlin; Stephen M Hewitt; Alfredo A Molinolo; Claudia Lanari; Caroline A Lamb
Journal:  Breast Cancer Res Treat       Date:  2011-11-29       Impact factor: 4.872

7.  De novo alu-element insertions in FGFR2 identify a distinct pathological basis for Apert syndrome.

Authors:  M Oldridge; E H Zackai; D M McDonald-McGinn; S Iseki; G M Morriss-Kay; S R Twigg; D Johnson; S A Wall; W Jiang; C Theda; E W Jabs; A O Wilkie
Journal:  Am J Hum Genet       Date:  1999-02       Impact factor: 11.025

8.  The prolactin receptor transactivation domain is associated with steroid hormone receptor expression and malignant progression of breast cancer.

Authors:  Alyson A Fiorillo; Terry R Medler; Yvonne B Feeney; Suzanne M Wetz; Kalie L Tommerdahl; Charles V Clevenger
Journal:  Am J Pathol       Date:  2012-11-14       Impact factor: 4.307

9.  Axl activates fibroblast growth factor receptor pathway to potentiate survival signals in B-cell chronic lymphocytic leukemia cells.

Authors:  S Sinha; J Boysen; M Nelson; S L Warner; D Bearss; N E Kay; A K Ghosh
Journal:  Leukemia       Date:  2015-11-24       Impact factor: 11.528

Review 10.  Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.

Authors:  Margaret A Knowles
Journal:  World J Urol       Date:  2007-10-03       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.